DE60135485D1 - Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa - Google Patents

Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa

Info

Publication number
DE60135485D1
DE60135485D1 DE60135485T DE60135485T DE60135485D1 DE 60135485 D1 DE60135485 D1 DE 60135485D1 DE 60135485 T DE60135485 T DE 60135485T DE 60135485 T DE60135485 T DE 60135485T DE 60135485 D1 DE60135485 D1 DE 60135485D1
Authority
DE
Germany
Prior art keywords
heterocycles
inhibitors
factor
monocyclic
bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135485T
Other languages
English (en)
Inventor
Irina C Jacobson
Ruth R Wexler
Jennifer Qiao
Suanne Nakajima
Mimi L Quan
Shuaige Wang
Joanne M Smallheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of DE60135485D1 publication Critical patent/DE60135485D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
DE60135485T 2000-11-06 2001-10-30 Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa Expired - Lifetime DE60135485D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24610700P 2000-11-06 2000-11-06
US31355201P 2001-08-20 2001-08-20
PCT/US2001/051621 WO2002102380A1 (en) 2000-11-06 2001-10-30 Monocyclic or bicyclic carbocycles and heterocycles as factor xa inhibitors

Publications (1)

Publication Number Publication Date
DE60135485D1 true DE60135485D1 (de) 2008-10-02

Family

ID=26937728

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135485T Expired - Lifetime DE60135485D1 (de) 2000-11-06 2001-10-30 Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa

Country Status (9)

Country Link
US (2) US6710058B2 (de)
EP (1) EP1337251B1 (de)
JP (1) JP2004536084A (de)
AT (1) ATE405266T1 (de)
CA (1) CA2429113A1 (de)
DE (1) DE60135485D1 (de)
ES (1) ES2310540T3 (de)
HU (1) HUP0401832A2 (de)
WO (1) WO2002102380A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
HUP0500027A2 (hu) * 2001-11-22 2005-04-28 Ono Pharmaceutical Co., Ltd. Piperidin-2-on-származékok és hatóanyagként ezeket tartalmazó gyógyászati készítmények
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
JPWO2004101529A1 (ja) * 2003-05-19 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314299D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
AR044805A1 (es) * 2003-06-19 2005-10-05 Glaxo Group Ltd Compuesto de (2-oxo-3-pirrolidinil) sulfonamida, composicion farmaceutica que lo comprende, su uso para prepararla, y proceso para preparar dicho compuesto
AU2004257289A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US8710232B2 (en) * 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
KR20070054246A (ko) * 2004-09-17 2007-05-28 유니버시티 오브 매사추세츠 리소좀성 효소 결핍을 위한 조성물 및 이의 용도
JPWO2006046575A1 (ja) 2004-10-26 2008-05-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の非晶質体
WO2006104280A1 (ja) * 2005-03-31 2006-10-05 Takeda Pharmaceutical Company Limited 糖尿病の予防・治療剤
CN101309916A (zh) * 2005-11-18 2008-11-19 卫材R&D管理有限公司 制备肉桂酰胺衍生物的方法
EP1953151A4 (de) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd Salze aus einer cynnamidverbindung oder solvate daraus
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EP2019094A4 (de) * 2006-05-19 2011-01-05 Eisai R&D Man Co Ltd Zimtsäureamidderivat vom heterocyclischen typ
US20100105904A1 (en) * 2006-05-19 2010-04-29 Teiji Kimura Urea type cinnamide derivative
PE20081791A1 (es) * 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd Dos derivados ciclicos de oxomorfolina
JPWO2008140111A1 (ja) * 2007-05-16 2010-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド誘導体のワンポット製造方法
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CL2008002542A1 (es) * 2007-08-31 2009-01-02 Eisai R&D Man Co Ltd Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
US20100317860A1 (en) * 2008-01-28 2010-12-16 Ikuo Kushida Crystalline cinnamide compounds or salts thereof
WO2009119528A1 (ja) * 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
DE102008035552A1 (de) * 2008-07-30 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Substituierte Pyridine und ihre Verwendung
EA201101396A1 (ru) 2009-04-02 2012-09-28 Мерк Патент Гмбх Ингибиторы аутотаксина
CN102369186B (zh) 2009-04-02 2014-07-09 默克专利有限公司 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物
WO2010150204A1 (en) * 2009-06-25 2010-12-29 Institut Univ. De Ciència I Tecnologia, S.A. N-(2-oxo-1-phenylpiperidin-3-yl) sulfonamides for the identification of biological and pharmacological activity
ES2354550B1 (es) 2009-06-26 2011-11-15 Institut Univ. De Ciència I Tecnologia, S.A. Biblioteca de n-(1-fenil-2-oxo-3-piperidil)sulfonamidas para el descubrimiento de fármacos.
BR112012029395A2 (pt) 2010-05-17 2016-07-26 Array Biopharma Inc lactamas piperdinil-substituídas como moduladores de gpr119
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
TWI447141B (zh) * 2010-08-04 2014-08-01 Apaq Technology Co Ltd 導電聚合物及其裝置
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
KR20130130737A (ko) 2010-11-11 2013-12-02 사노피 ３­（６­아미노­피리딘­３일）­２­아크릴산 유도체의 제조방법
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
WO2013012723A1 (en) 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
JP5957077B2 (ja) * 2011-07-13 2016-07-27 ノバルティス アーゲー タンキラーゼ阻害剤として使用するための４−ピペリジニル化合物
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
EP2751093A1 (de) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
SG11201406468YA (en) 2012-04-13 2015-01-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
EP2943482B1 (de) * 2013-01-09 2019-03-13 The Regents Of The University Of Michigan Gemischte disulfidkonjugaten von thienopyridin-verbindungen und deren verwendungen
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
AU2014337300B2 (en) 2013-10-16 2019-01-03 Eisai R&D Management Co., Ltd. Hydrochloride salt form for EZH2 inhibition
WO2015200650A1 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
SG11201906164RA (en) 2017-01-11 2019-08-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
EP3587416A1 (de) * 2018-06-29 2020-01-01 Institut Univ. de Ciència i Tecnologia, S.A. 2-oxopiperidin-3-yl-derivate und verwendung davon
EP3586847A1 (de) * 2018-06-29 2020-01-01 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Verbindungen zur verwendung bei der vorbeugung oder behandlung von krebs
CN109020874B (zh) * 2018-09-04 2021-09-24 上海雅本化学有限公司 一种阿哌沙班中间体及其制备方法
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP4356909A1 (de) 2022-10-17 2024-04-24 Selabtec Sciences, SLU 1(sulfonyl)-n-phenylpyrrolidin-2-carboxamid-derivate und ihre verwendung

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032602A (en) 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
EP0454444A1 (de) 1990-04-24 1991-10-30 Nissan Chemical Industries Ltd. Glutarimidderivate und Herbizide
GB9026389D0 (en) 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
DE69209576D1 (de) 1991-05-10 1996-05-09 Takeda Chemical Industries Ltd Pyridinderivate, deren Herstellung und Anwendung
CA2176043A1 (en) 1993-11-19 1995-05-26 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
CA2245811A1 (en) 1996-02-22 1997-08-28 Merck & Co., Inc. Pyridinone thrombin inhibitors
AU715603B2 (en) 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PL329441A1 (en) 1996-04-23 1999-03-29 Merck & Co Inc Pyrasinone-type thrombin inhibitors
WO1998009987A1 (en) 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
EP0971891A4 (de) 1997-01-22 2000-04-19 Merck & Co Inc Thrombin-inhibitoren
UA57081C2 (uk) 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування
EP0908764B1 (de) 1997-10-06 2002-03-27 Agfa-Gevaert Verfahren zur Verarbeitung eines photographischen Schwarzweiss-Silberhalogenidmaterials
WO1999031507A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
WO1999031506A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Parallel solution phase synthesis of lactams
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
HUP0202191A3 (en) 1999-05-19 2003-02-28 Pharmacia Corp Chicago Substituted polycyclic aryl and heteroaryl pirazinones useful for selective inhibition of the coagulation cascade and pharmaceutical compositions containing them
CN1152023C (zh) 1999-05-19 2004-06-02 法玛西雅公司 作为抗凝血剂的取代的多环芳基与杂芳基尿嘧啶
JP2002544262A (ja) 1999-05-19 2002-12-24 ファルマシア・コーポレイション 有用な抗凝血剤としての置換多環式アリールおよびヘテロアリールピリミジノン
PL352403A1 (en) 1999-05-19 2003-08-25 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Also Published As

Publication number Publication date
ES2310540T3 (es) 2009-01-16
ATE405266T1 (de) 2008-09-15
CA2429113A1 (en) 2002-12-27
HUP0401832A2 (hu) 2004-12-28
JP2004536084A (ja) 2004-12-02
US6710058B2 (en) 2004-03-23
US20040132718A1 (en) 2004-07-08
US20020183324A1 (en) 2002-12-05
US6951872B2 (en) 2005-10-04
WO2002102380A1 (en) 2002-12-27
EP1337251B1 (de) 2008-08-20
EP1337251A1 (de) 2003-08-27

Similar Documents

Publication Publication Date Title
DE60135485D1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
ATE241621T1 (de) Arylsulfonyle als faktor xa inhibitoren
EA200400361A1 (ru) Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
ATE266636T1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
ATE373655T1 (de) 1-(heteroaryl-phenyl)-kondensierte pyrazol- derivate als factor xa inhibitoren
ATE302775T1 (de) Carbolinderivate
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
ATE433981T1 (de) Heterocyclische verbindungen
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
NO20063324L (no) 3-cyano-kinolinderivater med antiproliferativ aktivitet
ATE346067T1 (de) Carbolinderivate
ATE477256T1 (de) Thienylverbindungen
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
DE60321810D1 (de) Neue tricyclische derivate als ltd4 antagonisten
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE391715T1 (de) Heterozyklische mutilinester und deren verwendung als bakterizide
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition